Table 1 Baseline clinicopathological characteristics of patients with gastric cancer (n = 163)
From: Prognostic value of noggin protein expression in patients with resected gastric cancer
Variables | Data |
|---|---|
Age, years, median (range) | 69.0 (35–92) |
  ≤ 70 | 93 (57.1) |
  >  70 | 70 (42.9) |
Sex | |
 Male | 117 (71.8) |
 Female | 46 (28.2) |
T stage | |
 T2 | 38 (23.3) |
 T3 | 47 (28.8) |
 T4 | 78 (47.9) |
N stage | |
 N0 | 58 (35.6) |
 N1 | 22 (13.5) |
 N2 | 22 (13.5) |
 N3 | 61 (37.4) |
Pathological stage | |
 I | 26 (16.0) |
 II | 44 (27.0) |
 III | 75 (46.0) |
 IV | 18 (11.0) |
WHO differentiation | |
 Well/moderate | 71 (43.6) |
 Poor | 90 (55.2) |
Lauren’s classification | |
 Intestinal type | 78 (47.9) |
 Non-intestinal typea | 85 (52.1) |
Lymphatic invasion | |
 No | 54 (33.1) |
 Yes | 109 (66.9) |
Vascular invasion | |
 No | 135 (82.8) |
 Yes | 28 (17.2) |
R0 resection | |
 No | 18 (11.0) |
 Yes | 145 (89.0) |
Adjuvant chemotherapy | |
 No | 91 (55.8) |
 Yes | 72 (44.2) |
EBV positivity | |
 No | 153 (93.9) |
 Yes | 10 (6.1) |
Peritoneal seeding | |
 Negative | 145 (89.0) |
 Positive | 18 (11.0) |